Renal Transplantation Center "A. Vercellone," Division of Nephrology, Dialysis and Transplantation, Department of Medical Sciences, Città Della Salute e Della Scienza Hospital and University of Turin, Italy, Corso Bramante, 88-10126, Turin, Italy
Auto-generated profile, based on publicly available information
Silvia Mingozzi
Renal Transplantation Center "A. Vercellone," Division of Nephrology, Dialysis and Transplantation, Department of Medical Sciences, Città Della Salute e Della Scienza Hospital and University of Turin, Italy, Corso Bramante, 88-10126, Turin, Italy
The recurrence of primary focal segmental glomerulosclerosis (FSGS) after kidney transplantation is associated with a high graft loss rate with standard treatments based on plasmapheresis with/without rituximab. We present two consecutive cases of non-genetic early severe recurrent FSGS refractory to rituximab and anti-interleukin-1 treatment and with a partial response to plasmapheresis. Case 1: a 22-year-old man was rescue-treated for recurrence 36 weeks after transplantation with obinutuzumab (1000 mg/1.73 m2, one dose) and daratumumab (18 mg/kg each dose, eight doses), resulting in plasmapheresis discontinuation and a drop of proteinuria from 29 to 2.3 g/day. Proteinuria increased with circulating CD38+ plasma cells, and responded to an additional daratumumab dose. Currently, the proteinuria is 1.8 g/day, 14.5 months after discontinuing plasmapheresis and starting obinutuzumab and daratumumab therapy. CASE 2: A 15-year-old girl was plasmapheresis-dependent with 2 g/day proteinuria 82 weeks after transplantation, with a Tesio® catheter in the right jugular vein as the only possible vascular access. After treatment with obinutuzumab and daratumumab (one dose each), she achieved stable complete remission (0.3 g/day proteinuria) with persistent plasmapheresis discontinuation. These cases suggest the potential of combining obinutuzumab with daratumumab for the treatment of recurrent FSGS.
23 August 2025 in American Journal of Transplantation
Current trials are exploring complement blockade in IgA nephropathy (IgAN) of native kidneys. No data are available on IgAN recurrence. Herein, we report on the first small case series (n = 5) treated with iptacopan, a factor B inhibitor targeting the alternative complement pathway, for this condition, providing biopsy findings after treatment. All patients underwent indication biopsies for proteinuria increase, graft function deterioration, and subsequent post-treatment biopsies. Three/5 were treated with iptacopan-only between the biopsies, whereas in 2/5, iptacopan treatment was preceded by either steroid pulse or steroid pulse plus plasmapheresis. Within 6-12 months, iptacopan led to a marked reduction in terminal complement component deposition (C5b-9) and almost disappearance of C3. In contrast, IgA deposition was slightly reduced. There was no consistent improvement of proteinuria. No major AE occurred. In conclusion, this is the first report of iptacopan use for recurrent IgAN in kidney transplant recipients. In addition, it demonstrates in vivo modulation of glomerular complement deposition, specifically preventing C3 deposition and C5b-9 fixation, which is considered a major effector mechanism of tissue injury. Large cohorts are required to define its impact on clinical outcomes in long-term transplant settings.